S. Hanauer, B. Feagan, and G. Lichtenstein, ACCENT I Study Group. Maintenance infliximab for Crohn's disease : the ACCENT I randomised trial, Lancet, 2002.

B. Sands, F. Anderson, and C. Bernstein, Infliximab Maintenance Therapy for Fistulizing Crohn's Disease, New England Journal of Medicine, vol.350, issue.9, pp.876-85, 2004.
DOI : 10.1056/NEJMoa030815

P. Rutgeerts, W. Sandborn, and B. Feagan, Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis, New England Journal of Medicine, vol.353, issue.23, pp.2462-76, 2005.
DOI : 10.1056/NEJMoa050516

L. Peyrin-biroulet, P. Deltenre, and N. De-suray, Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials, Clinical Gastroenterology and Hepatology, vol.6, issue.6, pp.644-53, 2008.
DOI : 10.1016/j.cgh.2008.03.014

G. Lichtenstein, S. Yan, and M. Bala, Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease, Gastroenterology, 2005.

B. Feagan, R. Panaccione, and W. Sandborn, Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study, Gastroenterology, vol.135, issue.5, pp.1493-1499, 2008.
DOI : 10.1053/j.gastro.2008.07.069

J. Gisbert and J. Panés, Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review, The American Journal of Gastroenterology, vol.118, issue.3, pp.760-767, 2009.
DOI : 10.1038/ajg.2008.88

D. Bie, C. Hummel, T. Kindermann, and A. , The duration of effect of infliximab maintenance treatment in paediatric Crohn???s disease is limited, Alimentary Pharmacology & Therapeutics, vol.38, issue.2, pp.243-50, 2011.
DOI : 10.1111/j.1365-2036.2010.04507.x

V. Crombé, J. Salleron, and G. Savoye, Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease : a population-based study, Inflamm Bowel Dis, 2011.

A. Assa, C. Hartman, and B. Weiss, Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease, Journal of Crohn's and Colitis, vol.7, issue.5, pp.369-76
DOI : 10.1016/j.crohns.2012.03.006

J. Hyams, T. Lerer, and A. Griffiths, Long-term outcome of maintenance infliximab therapy in children with Crohn??s disease, Inflammatory Bowel Diseases, vol.15, issue.6, pp.816-838, 2009.
DOI : 10.1002/ibd.20845

S. Clair, E. Wagner, C. Fasanmade, and A. , The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis : results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum, 2002.

F. Baert, M. Noman, and S. Vermeire, Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease, New England Journal of Medicine, vol.348, issue.7, pp.601-609, 2003.
DOI : 10.1056/NEJMoa020888

E. Maser, R. Villela, and M. Silverberg, Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn???s Disease, Clinical Gastroenterology and Hepatology, vol.4, issue.10, pp.1248-54, 2006.
DOI : 10.1016/j.cgh.2006.06.025

C. Seow, A. Newman, and S. Irwin, Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis, Gut, vol.59, issue.01, pp.49-54, 2010.
DOI : 10.1136/gut.2009.183095

A. Hämäläinen, T. Sipponen, and K. Kolho, Serum infliximab concentrations in pediatric inflammatory bowel disease, Scandinavian Journal of Gastroenterology, vol.107, issue.1, pp.35-41
DOI : 10.1056/NEJMoa020888

N. Singh, C. Rosenthal, and G. Melmed, Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.20, issue.10, pp.1708-1721, 2014.
DOI : 10.1097/MIB.0000000000000137

N. Vande-casteele, M. Ferrante, and G. Van-assche, Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease, Gastroenterology, vol.148, issue.7, pp.1320-1329, 2015.
DOI : 10.1053/j.gastro.2015.02.031

K. Bendtzen, P. Geborek, and M. Svenson, Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor ?? inhibitor infliximab, Arthritis & Rheumatism, vol.45, issue.12, pp.3782-3791, 2006.
DOI : 10.1002/art.22214

K. Bendtzen, M. Ainsworth, and C. Steenholdt, Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies, Scandinavian Journal of Gastroenterology, vol.30, issue.5, pp.774-81, 2009.
DOI : 10.1053/j.gastro.2006.11.041

R. Farrell, M. Alsahli, and Y. Jeen, Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial, Gastroenterology, vol.124, issue.4, 2003.
DOI : 10.1053/gast.2003.50145

S. Vermeire, M. Noman, and G. Van-assche, Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease, Gut, vol.56, issue.9, 2007.
DOI : 10.1136/gut.2006.099978

H. Bachelez and . Infliximab, Rémicade® Annales de Dermatologie et de Vénéréologie, pp.978-981, 2007.

M. Clark, J. Colombel, and B. Feagan, American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21???23, 2006, Gastroenterology, vol.133, issue.1, pp.312-351, 2006.
DOI : 10.1053/j.gastro.2007.05.006

A. Stallmach, S. Hagel, and T. Bruns, Adverse effects of biologics used for treating IBD, Best Practice & Research Clinical Gastroenterology, vol.24, issue.2, pp.167-82, 2010.
DOI : 10.1016/j.bpg.2010.01.002

S. Vermeire, G. Van-assche, and P. Rutgeerts, Serum sickness, encephalitis and other complications of anti-cytokine therapy, Best Practice & Research Clinical Gastroenterology, vol.23, issue.1, pp.101-113, 2009.
DOI : 10.1016/j.bpg.2008.12.005

S. Ben-horin, Y. Chowers, and B. Ungar, Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal, Alimentary Pharmacology & Therapeutics, vol.9, issue.Suppl. 1, 2015.
DOI : 10.1111/apt.13268

M. Flamant and X. Roblin, Could therapeutic drug monitoring of anti-TNF-? be useful to consider a de-escalation of treatment? Expert Opin Biol Ther, pp.1-3, 2015.

J. Colombel, B. Feagan, and W. Sandborn, Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.18, issue.2, pp.349-58, 2012.
DOI : 10.1002/ibd.21831

J. Hyams, J. Markowitz, and A. Otley, Evaluation of the Pediatric Crohn Disease Activity Index: A Prospective Multicenter Experience, Journal of Pediatric Gastroenterology and Nutrition, vol.41, issue.4, pp.416-421, 2005.
DOI : 10.1097/01.mpg.0000183350.46795.42

D. Turner, A. Otley, and D. Mack, Development, Validation, and Evaluation of a Pediatric Ulcerative Colitis Activity Index: A Prospective Multicenter Study, Gastroenterology, vol.133, issue.2, 2007.
DOI : 10.1053/j.gastro.2007.05.029

F. Cameron, M. Wilson, and N. Basheer, Anti-TNF therapy for paediatric IBD: the Scottish national experience, Archives of Disease in Childhood, vol.7, issue.(Suppl A), pp.399-405, 2015.
DOI : 10.1136/archdischild-2013-305812

S. Vermeire, F. Gabriel, and V. Ballet, The effect of dose escalation on trough levels in patients who lost response to infliximab, Gut, vol.59, issue.3, p.81, 2010.

O. Adedokun, W. Sandborn, and B. Feagan, Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis, Gastroenterology, vol.147, issue.6, p.2014
DOI : 10.1053/j.gastro.2014.08.035

F. Cornillie, S. Hanauer, and R. Diamond, Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial, Gut, vol.362, issue.(Suppl 1), pp.1721-1728, 2014.
DOI : 10.1136/gutjnl-2012-304094

M. Bortlik, D. Duricova, and K. Malickova, Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease, Journal of Crohn's and Colitis, vol.7, issue.9, pp.736-779, 2013.
DOI : 10.1016/j.crohns.2012.10.019

D. Drobne, P. Bossuyt, and C. Breynaert, Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn???s Disease, Clinical Gastroenterology and Hepatology, vol.13, issue.3, pp.514-521
DOI : 10.1016/j.cgh.2014.07.027

N. Vande-casteele, R. Khanna, and B. Levesque, The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease, Gut, vol.9, issue.10, p.2015
DOI : 10.1136/gutjnl-2014-307883

O. Meara, S. Nanda, K. Moss, and A. , O-003???Relationship Between Vedolizumab Pharmacokinetics and Endoscopic Outcomes of Patients With Ulcerative Colitis, Inflammatory Bowel Diseases, vol.20, issue.1, pp.1-6, 2014.
DOI : 10.1097/01.MIB.0000456699.04243.9e

A. Moss, N. Fernandez-becker, J. Kim, and K. , The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.132, issue.Suppl. 1, 2008.
DOI : 10.1111/j.1365-2036.2008.03734.x

N. Zitomersky, B. Atkinson, and K. Fournier, Antibodies to Infliximab Are Associated with Lower Infliximab Levels and Increased Likelihood of Surgery in Pediatric IBD, Inflammatory Bowel Diseases, vol.21, issue.2, pp.307-321, 2015.
DOI : 10.1097/MIB.0000000000000284

F. Nuti, F. Viola, and F. Civitelli, Biological Therapy in a Pediatric Crohn Disease Population at a Referral Center, Journal of Pediatric Gastroenterology and Nutrition, vol.58, issue.5, pp.582-589, 2014.
DOI : 10.1097/MPG.0000000000000276

I. Dotan, R. Y. Yanai, and H. , Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.20, issue.12, pp.2247-59, 2014.
DOI : 10.1097/MIB.0000000000000212

T. Mälkönen, A. Wikström, and K. Heiskanen, Skin reactions during anti-TNF? therapy for pediatric inflammatory bowel disease : a 2-year prospective study, Inflamm Bowel Dis, 2014.

G. Mocci, M. Marzo, and A. Papa, Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease, Journal of Crohn's and Colitis, vol.7, issue.10, pp.769-79, 2013.
DOI : 10.1016/j.crohns.2013.01.009

M. Sherlock, T. Walters, and M. Tabbers, Infliximab-Induced Psoriasis and Psoriasiform Skin Lesions in Pediatric Crohn Disease and a Potential Association With IL-23 Receptor Polymorphisms, Journal of Pediatric Gastroenterology and Nutrition, vol.56, issue.5, pp.512-520, 2013.
DOI : 10.1097/MPG.0b013e31828390ba

C. Tillack, L. Ehmann, and M. Friedrich, Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterized by interferon-gammaexpressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment, Gut, vol.63, issue.4, pp.2014567-77

M. Frederiksen, M. Ainsworth, and J. Brynskov, Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD, Inflammatory Bowel Diseases, vol.20, issue.10, pp.1714-1735, 2014.
DOI : 10.1097/MIB.0000000000000138

S. Caimmi, D. Caimmi, and S. Riscassi, A New Pediatric Protocol for Rapid Desensitization to Monoclonal Antibodies, International Archives of Allergy and Immunology, vol.165, issue.3, pp.214-222, 2014.
DOI : 10.1159/000369299